Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00446290
Status:
COMPLETED
Last Update Posted:
2020-01-18
First Post:
2007-03-09
Brief Title:
Study of Docetaxel Capecitabine and Oxaliplatin in Advanced Stomach Cancer
Sponsor:
Asan Medical Center
Organization:
Asan Medical Center
Study Overview
Official Title:
A Phase I Study of Docetaxel Capecitabine and Oxaliplatin DXO in Patients With Advanced Stomach Cancer
Status:
COMPLETED
Status Verified Date:
2020-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Considering synergism between docetaxel D capecitabine X and oxaliplatin O and favourable toxicity profile of oxaliplatin over cisplatin it is to be expected that combination of docetaxel capecitabine and oxaliplatin DXO will be more effective than other regimens and feasible in advanced gastric cancer DXO regimen can be also easily administered on out-patient setting However so far DXO combination has not been tried in advanced gastric cancer The investigators will determine maximum tolerated dose of DXO regimen in this phase I study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None